Landmark Study Shows AI Boosts Clinical Trial Matching

Massive Bio publishes prospective data on using AI to scale cancer trial enrollment.

Apr. 9, 2026 at 3:41pm

Got story updates? Submit your updates here. ›

A highly abstract, textured painting in soft blues, greens, and oranges, featuring sweeping geometric shapes and precise botanical spirals that conceptually represent the complex algorithms and data flows of an AI-powered clinical trial matching system.AI-powered platforms are revolutionizing how cancer patients are matched to clinical trials, accelerating the development of new treatments.Boca Raton Today

Massive Bio, a leading oncology-focused clinical trial matching platform, has published a landmark prospective study demonstrating the effectiveness of its AI-driven approach to connecting cancer patients with appropriate clinical trials. The study, which involved 3,804 patients, found that Massive Bio's technology was able to significantly increase the rate of successful trial enrollment compared to traditional methods.

Why it matters

Clinical trial enrollment remains a major challenge in cancer research, with many eligible patients never making it into studies due to the complexity of the matching process. This study suggests that AI-powered platforms like Massive Bio's can help address this issue by automating and scaling the identification of suitable trials, potentially accelerating the development of new cancer treatments.

The details

The prospective study followed Massive Bio's process of using natural language processing and machine learning to analyze patient medical records and match them to open clinical trials. Researchers found that the AI-driven approach resulted in a 42% increase in the rate of successful trial enrollment compared to manual methods.

  • The study was conducted over a 12-month period from April 2025 to April 2026.

The players

Massive Bio

A leading oncology-focused clinical trial matching platform that uses AI to connect cancer patients with appropriate studies.

Got photos? Submit your photos here. ›

What they’re saying

“This landmark study demonstrates the power of AI to transform and scale clinical trial enrollment, which has long been a major bottleneck in cancer research.”

— Selin Kurnaz, CEO of Massive Bio

The takeaway

By leveraging AI to automate and streamline the complex process of matching cancer patients to clinical trials, platforms like Massive Bio's have the potential to dramatically improve enrollment and accelerate the development of new therapies.